. Overview Supernus Pharmaceuticals,Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and ch...
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-02 | 2025-12-31 | 0001356576-26-000011 | EDGAR | 109K words |
| 2025-02-25 | 2024-12-31 | 0001356576-25-000017 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0001356576-24-000013 | EDGAR | — |
| 2023-03-09 | 2022-12-31 | 0001356576-23-000016 | EDGAR | — |
| 2022-04-13 | 2021-12-31 | 0001356576-22-000025 | EDGAR | — |
| 2021-03-08 | 2020-12-31 | 0001356576-21-000028 | EDGAR | — |
| 2020-02-28 | 2019-12-31 | 0001356576-20-000010 | EDGAR | — |
| 2019-03-01 | 2018-12-31 | 0001047469-19-000828 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001047469-18-001210 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001047469-17-001684 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001356576-25-000071 | EDGAR | 42K words |
| 2025-08-05 | 2025-06-30 | 0001356576-25-000055 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0001356576-25-000033 | EDGAR | — |
| 2024-11-04 | 2024-09-30 | 0001356576-24-000067 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001356576-24-000051 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0001356576-24-000028 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001356576-23-000072 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001356576-23-000050 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001356576-23-000034 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001356576-22-000076 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001356576-22-000057 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001356576-22-000046 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-24 | 0001356576-26-000007 | EDGAR | 1K words |
| 2026-02-24 | 0001356576-26-000004 | EDGAR | — |
| 2026-02-12 | 0001356576-26-000002 | EDGAR | — |
| 2026-01-28 | 0001628280-26-003907 | EDGAR | — |
| 2025-11-04 | 0001356576-25-000068 | EDGAR | — |
| 2025-10-21 | 0001356576-25-000065 | EDGAR | — |
| 2025-08-05 | 0001356576-25-000053 | EDGAR | — |
| 2025-08-04 | 0001356576-25-000050 | EDGAR | — |
| 2025-07-31 | 0001104659-25-072506 | EDGAR | — |
| 2025-07-22 | 0001356576-25-000046 | EDGAR | — |
340 total filings indexed. 308 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001356576 |
| Ticker | SUPN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.supernus.com |
| Listed | 2012-05-01 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report